Rossi Rossana, De Palma Antonella, Benazzi Louise, Riccio Anna Maria, Canonica Giorgio Walter, Mauri Pierluigi
Institute for Biomedical Technologies (ITB-CNR), Proteomics and Metabolomics Unit, Segrate, MI, Italy.
Proteomics Clin Appl. 2014 Dec;8(11-12):901-15. doi: 10.1002/prca.201300108. Epub 2014 Oct 30.
Asthma and chronic obstructive pulmonary disease (COPD) are multifactorial respiratory diseases, characterized by reversible and irreversible airway obstruction, respectively. Even if the primary causes of these diseases remain unknown, inflammation is a central feature that leads to progressive and permanent pulmonary tissue damage (airway remodeling) up to the total loss of lung function. Therefore, the elucidation of the inflammation mechanisms and the characterization of the biological pathways, involved in asthma and COPD pathogenesis, are relevant in finding new possible diagnostic/prognostic biomarkers and for the validation of new drug targets. In this context, current advances in proteomic approaches, especially those based on MS, provide new tools to facilitate the discovery-driven studies of new biomarkers in respiratory diseases and improve the clinical reliability of the next generation of biomarkers for these diseases consisting of multiple phenotypes. This review will report an overview of the current proteomic methods applied to the discovery of candidate biomarkers for asthma and COPD, giving a special emphasis to emerging MS-based techniques.
哮喘和慢性阻塞性肺疾病（COPD）是多因素呼吸系统疾病，分别以可逆性和不可逆性气道阻塞为特征。即使这些疾病的主要病因尚不清楚，但炎症是导致进行性和永久性肺组织损伤（气道重塑）直至肺功能完全丧失的核心特征。因此，阐明哮喘和COPD发病机制中的炎症机制以及生物学途径的特征，对于寻找新的可能的诊断/预后生物标志物以及验证新的药物靶点具有重要意义。在这种背景下，蛋白质组学方法的当前进展，尤其是基于质谱（MS）的方法，提供了新的工具，以促进对呼吸系统疾病新生物标志物的发现驱动研究，并提高由多种表型组成的这些疾病的下一代生物标志物的临床可靠性。本综述将概述当前应用于发现哮喘和COPD候选生物标志物的蛋白质组学方法，特别强调新兴的基于MS的技术。
